SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health , providing enhanced care to their 150,000 members.

SAN DIEGO , May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has provided pricing for AVISE ® Lupus. Noridian’s decision to price AVISE Lupus follows the approval by

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March SAN DIEGO , May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended

SAN DIEGO , May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those

SAN DIEGO , April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022 , after the market close on Wednesday, May 11, 2022 . Ron Rocca , Exagen’s President and Chief Executive

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conference , which takes place May 3 rd - 4 th , 2022, in New York City at the Westin New York Grand Central

SAN DIEGO , March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members.

SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE ® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022 , AVISE test offerings become an

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported

SAN DIEGO , March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with appointment of seven doctors and rheumatology experts.